Go
To Index
Page
Herbal therapeutic treatment for prostate
cancer Washington: A
novel herb-based therapeutic called Zyflamend has been found to be linked with
minimal toxicity and no serious adverse events in men at high-risk for developing
prostate cancer in its phase I clinical trial. The trial was led by researcher
from the Center for Holistic Urology at Columbia University Medical Center and
NewYork-Presbyterian Hospital/Columbia. Writing in the Journal of the Society
for Integrative Oncology, the researchers revealed that 23 men aged 40-75 years,
who were diagnosed with an increased risk of developing prostate cancer, were
admitted into this prospective clinical trial to determine the safety and tolerability
of Zyflamend when administered orally for 18-months, either alone or along with
various dietary supplements. "Since we know that men with HGPIN have an increased
risk for developing prostate cancer, new strategies formulated to decrease cancer
risk, prevent or delay surgery, and improve quality of life, will be greatly beneficial
for these men," said senior author of the study Dr. Aaron E. Katz, an associate
professor of Urology at Columbia University College of Physicians and Surgeons.
The researchers say that basic science studies have suggested that Zyflamend may
have an anti-inflammatory mechanism of action, and the agent has been found to
be effective in decreasing the proliferation of prostate cancer in cell culture.
"Our results confirm that Zyflamend, in a dose of three times daily for up to
18-months, was well tolerated," said Dr. Jillian L. Capodice, director of the
Acupuncture Research and Integrative Clinical Service of the Department of Urology's
Center for Holistic Urology, at Columbia University College of Physicians and
Surgeons. -May 23,
2009 |